Security
Regeneron Pharmaceuticals, Inc. Common Stock · REGN
REGNNASDAQCommon stockCurrentCIK 872589Updated Nov 6, 2026
Name history
REGENERON PHARMACEUTICALS INC · through Jun 19, 2019
REGN price & chart
Loading TradingView…
NASDAQ:REGN on TradingView ↗About the company
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
In the news
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN ↗
Recent filings
13F-HR filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Entry into a Material Definitive Agreement · Results of Operations and Financial Condition · Other Events
Items 1.01, 2.02, 8.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 40,169,400,000Source | 37,441,900,000Source | 41,730,600,000Source | 38,219,200,000Source | 36,086,800,000Source | 40,868,800,000Source | 37,545,200,000Source | 34,369,600,000Source | 40,558,700,000Source | 37,759,400,000Source | 33,080,200,000Source | 29,214,500,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 1,380,900,000Source | 1,120,100,000Source | 1,309,800,000Source | 1,351,700,000Source | 1,102,200,000Source | 1,286,900,000Source | 1,167,000,000Source | 1,058,700,000Source | 1,257,400,000Source | 1,148,600,000Source | 1,038,600,000Source | 915,500,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,506,400,000Source | 2,011,800,000Source | 2,455,800,000Source | 1,995,800,000Source | 1,920,700,000Source | 2,962,600,000Source | 3,090,200,000Source | 2,602,000,000Source | 3,118,100,000Source | 2,488,200,000Source | 2,730,000,000Source | 3,105,900,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 5,687,100,000Source | 6,107,100,000Source | 6,565,400,000Source | 5,610,000,000Source | 5,717,100,000Source | 5,731,000,000Source | 5,561,000,000Source | 5,222,200,000Source | 5,741,100,000Source | 6,211,900,000Source | 5,667,300,000Source | 5,328,700,000Source |
| Inventory, NetUSD | 3,254,400,000Source | 3,018,000,000Source | 3,084,300,000Source | 3,205,600,000Source | 2,873,600,000Source | 3,103,600,000Source | 3,192,400,000Source | 2,714,900,000Source | 3,200,800,000Source | 3,087,300,000Source | 2,580,500,000Source | 2,401,900,000Source |
| Assets, CurrentUSD | 17,980,700,000Source | 19,333,600,000Source | 18,446,000,000Source | 16,859,500,000Source | 19,081,600,000Source | 18,209,200,000Source | 17,571,700,000Source | 18,871,500,000Source | 18,021,900,000Source | 18,660,900,000Source | 19,479,200,000Source | 15,884,100,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 595,600,000Source | 412,000,000Source | 801,700,000Source | 574,300,000Source | 681,900,000Source | 620,900,000Source | 468,900,000Source | 414,900,000Source | 474,800,000Source | 349,200,000Source | 386,600,000Source | 411,200,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | 245,800,000Source | 217,400,000Source | 78,000,000Source | — |
| Other Assets, NoncurrentUSD | 1,673,100,000Source | 1,043,000,000Source | 2,306,200,000Source | 1,536,900,000Source | 993,800,000Source | 2,129,700,000Source | 1,393,100,000Source | 470,200,000Source | 1,821,200,000Source | 1,136,000,000Source | 444,100,000Source | 336,400,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 9,211,600,000Source | 8,116,000,000Source | 10,019,200,000Source | 8,280,300,000Source | 7,881,000,000Source | 9,445,200,000Source | 8,157,600,000Source | 7,378,500,000Source | 9,301,800,000Source | 8,405,800,000Source | 7,107,100,000Source | 6,550,500,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Additional Paid in CapitalUSD | 13,787,300,000Source | 12,702,800,000Source | 14,700,600,000Source | 13,490,800,000Source | 12,316,900,000Source | 14,401,300,000Source | 13,192,100,000Source | 11,942,600,000Source | 13,995,000,000Source | 12,855,900,000Source | 11,354,000,000Source | 9,949,300,000Source |
| Retained Earnings (Accumulated Deficit)USD | 35,045,800,000Source | 30,755,200,000Source | 37,621,400,000Source | 33,680,200,000Source | 29,414,600,000Source | 36,423,800,000Source | 32,384,400,000Source | 27,982,300,000Source | 35,797,100,000Source | 31,672,900,000Source | 27,260,300,000Source | 23,306,700,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 69,000,000Source | 60,200,000Source | -35,800,000Source | 52,500,000Source | -69,900,000Source | 11,900,000Source | 29,100,000Source | -77,200,000Source | 77,500,000Source | -7,900,000Source | -80,900,000Source | -238,800,000Source |
| Stockholders' Equity Attributable to ParentUSD | 30,957,800,000Source | 29,325,900,000Source | 31,711,400,000Source | 29,938,900,000Source | 28,205,800,000Source | 31,423,600,000Source | 29,387,600,000Source | 26,991,100,000Source | 31,256,900,000Source | 29,353,600,000Source | 25,973,100,000Source | 22,664,000,000Source |
| Liabilities and EquityUSD | 40,169,400,000Source | 37,441,900,000Source | 41,730,600,000Source | 38,219,200,000Source | 36,086,800,000Source | 40,868,800,000Source | 37,545,200,000Source | 34,369,600,000Source | 40,558,700,000Source | 37,759,400,000Source | 33,080,200,000Source | 29,214,500,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 4,425,100,000Source | 3,661,000,000Source | 5,530,600,000Source | 3,667,000,000Source | 3,508,600,000Source | 5,107,700,000Source | 3,566,600,000Source | 3,580,900,000Source | 4,368,400,000Source | 3,944,300,000Source | 3,423,400,000Source | 3,141,300,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | 37,800,000Source | 30,300,000Source | 19,000,000Source | — |
| Accounts Payable, CurrentUSD | 903,800,000Source | 497,300,000Source | 1,159,300,000Source | 723,900,000Source | 561,700,000Source | 1,027,100,000Source | 705,500,000Source | 671,300,000Source | 939,000,000Source | 789,500,000Source | 606,600,000Source | 589,200,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | 229,000,000Source | 204,100,000Source | 68,700,000Source | — |
| Other Liabilities, NoncurrentUSD | 1,861,800,000Source | 1,543,600,000Source | 2,281,600,000Source | 1,701,900,000Source | 1,463,200,000Source | 2,126,200,000Source | 1,674,400,000Source | 908,500,000Source | 2,018,800,000Source | 1,571,400,000Source | 854,100,000Source | 638,000,000Source |
| Additional Financial Items | ||||||||||||
| Long-term Debt, Excluding Current MaturitiesUSD | 1,985,500,000Source | 1,984,000,000Source | 1,986,600,000Source | 1,985,100,000Source | 1,983,600,000Source | 1,986,200,000Source | 1,984,800,000Source | 1,983,300,000Source | 1,985,900,000Source | 1,984,400,000Source | 1,982,900,000Source | 1,981,400,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 123,200,000Source | 126,900,000Source | 543,700,000Source | 482,900,000Source | 421,000,000Source | 341,400,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 257,400,000Source | 255,700,000Source | 993,700,000Source | 982,800,000Source | 885,000,000Source | 725,000,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -1,200,000Source | -657,800,000Source | -498,100,000Source | 554,000,000Source | 338,800,000Source | -707,800,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -26,600,000Source | 152,300,000Source | 275,300,000Source | 619,700,000Source | 271,700,000Source | 696,500,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -785,400,000Source | -757,300,000Source | -837,800,000Source | -746,400,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 1,078,900,000Source | 1,045,100,000Source | 4,978,900,000Source | 4,420,500,000Source | 4,594,000,000Source | 5,014,900,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | 3,300,000Source | 16,500,000Source | 54,900,000Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -428,900,000Source | 647,500,000Source | -629,100,000Source | -2,468,100,000Source | -3,185,100,000Source | -3,784,600,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 73,200,000Source | 4,300,000Source | 532,100,000Source | 1,029,100,000Source | 700,600,000Source | 445,700,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 794,300,000Source | 1,041,400,000Source | 3,438,600,000Source | 2,603,300,000Source | 2,235,000,000Source | 2,082,800,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -802,200,000Source | -1,089,200,000Source | -3,715,400,000Source | -2,200,500,000Source | -1,790,100,000Source | -1,009,000,000Source |
| Dividends paid | — | — | — | — | — | — | —Source | —Source | —Source | — | — | — |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | 0Source | -10,300,000Source | -10,300,000Source | -33,400,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -153,100,000Source | 604,000,000Source | 634,700,000Source | -248,800,000Source | -381,600,000Source | 221,300,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 2,513,100,000Source | 2,011,800,000Source | 2,466,000,000Source | 2,015,600,000Source | 2,970,600,000Source | 3,093,000,000Source | 3,123,700,000Source | 2,489,000,000Source | 2,737,800,000Source | 3,119,400,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 41,600,000Source | 52,600,000Source | 73,100,000Source | 53,700,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 1,253,000,000Source | 743,000,000Source | 870,300,000Source | 1,502,400,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -900,000Source | 600,000Source | 300,000Source | -700,000Source | -400,000Source | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 178,800,000Source | 128,900,000Source | 92,200,000Source | — |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | 581,500,000Source | 134,500,000Source | — | — | — | — | 955,600,000Source | — | — | — |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | 370,900,000Source | 0Source | — | — | — | — | 966,200,000Source | — | — | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | 210,600,000Source | 134,500,000Source | 61,400,000Source | 249,800,000Source | 24,000,000Source | 139,700,000Source | -10,600,000Source | 117,700,000Source | -237,800,000Source | -39,800,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | — | — | — | — | — | — | — | — | — | — | 29,000,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 303,300,000Source | 152,400,000Source | 230,900,000Source | 127,100,000Source | 104,000,000Source | 96,300,000Source | 725,800,000Source | 367,300,000Source | 245,700,000Source | 520,400,000Source |
| InterestExpenseNonoperatingUSD | — | — | 19,300,000Source | 13,800,000Source | 11,000,000Source | 3,600,000Source | 12,900,000Source | 8,700,000Source | 43,800,000Source | 55,200,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | 172,900,000Source | 126,300,000Source | 102,300,000Source | 258,700,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 1,460,000,000Source | 1,340,600,000Source | 1,296,900,000Source | 1,391,600,000Source | 727,200,000Source | 808,700,000Source | 4,504,900,000Source | 4,412,600,000Source | 3,953,600,000Source | 4,338,400,000Source |
| Nonoperating Income (Expense)USD | — | — | 736,500,000Source | 313,500,000Source | 234,300,000Source | 439,200,000Source | 188,300,000Source | 313,300,000Source | 1,652,800,000Source | 789,200,000Source | 152,200,000Source | 119,900,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 755,800,000Source | 327,300,000Source | 245,300,000Source | 442,800,000Source | 201,200,000Source | 322,000,000Source | 1,696,600,000Source | 844,400,000Source | 225,200,000Source | 179,300,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 10,000,000Source | -8,000,000Source | — | 0Source | — | 0Source | 10,000,000Source | -53,400,000Source | 2,100,000Source | 89,900,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 163,100,000Source | 60,600,000Source | 635,900,000Source | 1,465,300,000Source | 1,145,500,000Source | 1,519,500,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 3,754,300,000Source | 3,720,700,000Source | 4,290,700,000Source | 3,675,600,000Source | 3,605,400,000Source | 3,028,700,000Source | 14,342,900,000Source | 14,202,000,000Source | 13,117,200,000Source | 12,172,900,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 657,800,000Source | 714,400,000Source | 662,100,000Source | 634,200,000Source | 647,700,000Source | 633,000,000Source | 2,700,000,000Source | 2,954,400,000Source | 2,631,300,000Source | 2,115,900,000Source |
| Operating Income (Loss)USD | — | — | 1,026,800,000Source | 1,179,500,000Source | 1,293,500,000Source | 1,079,500,000Source | 642,900,000Source | 591,700,000Source | 3,577,900,000Source | 3,990,700,000Source | 4,047,100,000Source | 4,738,900,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 755,800,000Source | 327,300,000Source | 245,300,000Source | 442,800,000Source | 201,200,000Source | 322,000,000Source | 1,696,600,000Source | 844,400,000Source | 225,200,000Source | 179,300,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 1,763,300,000Source | 1,493,000,000Source | 1,527,800,000Source | 1,518,700,000Source | 831,200,000Source | 905,000,000Source | 5,230,700,000Source | 4,779,900,000Source | 4,199,300,000Source | 4,858,800,000Source |
| Income Tax Expense (Benefit)USD | — | — | 303,300,000Source | 152,400,000Source | 230,900,000Source | 127,100,000Source | 104,000,000Source | 96,300,000Source | 725,800,000Source | 367,300,000Source | 245,700,000Source | 520,400,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 1,460,000,000Source | 1,340,600,000Source | 1,296,900,000Source | 1,391,600,000Source | 727,200,000Source | 808,700,000Source | 4,504,900,000Source | 4,412,600,000Source | 3,953,600,000Source | 4,338,400,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 14.09Source | 12.4Source | 12.62Source | 13.24Source | 6.99Source | 7.58Source | 43.07Source | 40.9Source | 37.05Source | 40.51Source |
| Earnings Per Share, DilutedUSD per share | — | — | 13.62Source | 11.54Source | 12.23Source | 12.81Source | 6.75Source | 7.27Source | 41.48Source | 38.34Source | 34.77Source | 38.22Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 103,600,000Source | 108,100,000Source | 102,800,000Source | 105,100,000Source | 104,000,000Source | 106,700,000Source | 104,600,000Source | 107,900,000Source | 106,700,000Source | 107,100,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 107,200,000Source | 116,200,000Source | 106,000,000Source | 108,600,000Source | 107,700,000Source | 111,200,000Source | 108,600,000Source | 115,100,000Source | 113,700,000Source | 113,500,000Source |
| Interest Expense (non-operating)USD | — | — | 19,300,000Source | 13,800,000Source | 11,000,000Source | 3,600,000Source | 12,900,000Source | 8,700,000Source | 43,800,000Source | 55,200,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 178,800,000Source | 128,900,000Source | 92,200,000Source | — |
| Costs and ExpensesUSD | — | — | 2,727,500,000Source | 2,541,200,000Source | 2,997,200,000Source | 2,596,100,000Source | 2,962,500,000Source | 2,437,000,000Source | 10,765,000,000Source | 10,211,300,000Source | 9,070,100,000Source | 7,434,000,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,511,200,000Source | 1,124,600,000Source | 1,083,500,000Source | 1,266,800,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | 370,900,000Source | 0Source | — | — | — | — | 966,200,000Source | — | — | — |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | — | — | — | — | — | — | — | — | — | — | 29,000,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -476,300,000Source | -411,300,000Source | -362,300,000Source | 839,900,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 73,000,000Source | 59,400,000Source |
| Interest Income, Debt Securities, OperatingUSD | — | — | — | — | — | — | — | — | 716,800,000Source | 711,400,000Source | 495,900,000Source | 160,100,000Source |
| Nonoperating Income (Expense)USD | — | — | 736,500,000Source | 313,500,000Source | 234,300,000Source | 439,200,000Source | 188,300,000Source | 313,300,000Source | 1,652,800,000Source | 789,200,000Source | 152,200,000Source | 119,900,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 10,000,000Source | -8,000,000Source | — | 0Source | — | 0Source | 10,000,000Source | -53,400,000Source | 2,100,000Source | 89,900,000Source |
| Research and Development ExpenseUSD | — | — | 1,475,000,000Source | 1,271,500,000Source | 1,631,600,000Source | 1,421,700,000Source | 1,543,500,000Source | 1,327,400,000Source | 5,850,200,000Source | 5,132,000,000Source | 4,439,000,000Source | 3,592,500,000Source |
| Common Stock, Dividends, Per Share, Declared | — | — | —Source | — | —Source | —Source | —Source | — | — | — | — | — |
Filing attachments
tm2626090d1_ex99-1.htm · 8-K · 2026-09-30
Exhibit 99.1 Supplemental Information Regarding Award Rationale, Design Process, and Key Terms Note: See definitions set forth under “1. New Equity Awards for CEO and CSO” in Item 5.02 of this Current Report on Form 8-K for capitalized terms used but not defined below. Award Rationale and Design Process The 2026 PSUs were approved after a rigorous, multi-year process led by the Compensation Committee, incorporating long-term strategic considerations and informed by direct feedback from many …
Read attachment ↗regn-ex_41x12312025x10k.htm · 10-K · 2026-02-04
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the common stock, par value $0.001 per share (the “Common Stock”), of Regeneron Pharmaceuticals, Inc. (the “Company”) which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following also contains a description of the Class A Stock, par…
Read attachment ↗tm262861d1_ex99-1.htm · 8-K · 2026-01-12
EX-99.1 2 tm262861d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 J a n u a r y 1 2, 2 0 2 6 J.P. Morgan Healthcare Conference This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 2 J.P. Morgan Healthcare Conference Dr. Leonard Schleifer, MD, PhD Board Co-…
Read attachment ↗tm253014d1_ex99-1.htm · 8-K · 2025-01-13
EX-99.1 2 tm253014d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press Release Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference Dupixent ® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role EYLEA HD ® and EYLEA ® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sal…
Read attachment ↗tm253014d1_ex99-2.htm · 8-K · 2025-01-13
EX-99.2 3 tm253014d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 J.P. Morgan Healthcare Conference JANUARY 13, 2025 This non - promotional presentation contains investigational data as well as forward - looking statements; actual results may vary m aterially. 2 Strategy & Business Update J.P. Morgan Healthcare Conference 2025 Leonard S. Schleifer, MD, PhD Co - Founder, Board Co - Chair, President & Chief Executive Officer 3 Note regarding forward - looking statements This presentation includes f…
Read attachment ↗